Dr Reddy's Laboratories Ltd (RDY)

47.87
0.04 0.08
NYSE : Health Care
Prev Close 47.83
Open 47.88
Day Low/High 47.34 / 48.07
52 Wk Low/High 40.67 / 68.00
Volume 181.25K
Avg Volume 333.50K
Exchange NYSE
Shares Outstanding 165.53M
Market Cap 7.83B
EPS 1.80
P/E Ratio 26.73
Div & Yield 0.30 (0.60%)

Latest News

Dr. Reddy's Listed On Dow Jones Sustainability Indices 2016

Dr. Reddy's Listed On Dow Jones Sustainability Indices 2016

Dr. Reddy's Laboratories Ltd.

Dr. Reddy's Laboratories Announces The Launch Of Bupropion HCl Extended-Release Tablets, USP (SR) In The U.S. Market

Dr. Reddy's Laboratories Announces The Launch Of Bupropion HCl Extended-Release Tablets, USP (SR) In The U.S. Market

Dr. Reddy's Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that it has launched Bupropion HCl extended-release tablets, USP (SR) in 100 mg, 150 mg and 200 mg, a therapeutic equivalent generic...

Dr. Reddy's Announces Purple Health, A Unique Patient-Centric Platform That Takes Care Beyond The Pill

Dr. Reddy's Announces Purple Health, A Unique Patient-Centric Platform That Takes Care Beyond The Pill

Dr. Reddy's Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY) today announced the launch of Purple Health, a unique platform designed to inspire patient-centric innovation and deliver solutions that address unmet...

Dr. Reddy's Laboratories Launches Nitroglycerin Sublingual Tablets USP In The U.S. Market Hyderabad, India, August 29, 2016

Dr. Reddy's Laboratories Launches Nitroglycerin Sublingual Tablets USP In The U.S. Market Hyderabad, India, August 29, 2016

Dr. Reddy's Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that it has launched Nitroglycerin sublingual tablets USP, 0.

Changing Landscape for Generic-Drug Makers Creates Opportunities

Changing Landscape for Generic-Drug Makers Creates Opportunities

The generic-drug industry has undergone a flurry of acquisition activity over the past 18 months, highlighted by the long-anticipated but only recent closing of Teva Pharmaceutical's purchase of Allergan's generics.

Dr. Reddy's Completes Acquisition Of Product Portfolio From TEVA

Dr. Reddy's Completes Acquisition Of Product Portfolio From TEVA

Dr. Reddy's Laboratories Ltd.

Dr. Reddy's Q1 FY17 Financial Results

Dr. Reddy's Q1 FY17 Financial Results

Dr. Reddy's Laboratories Ltd.

Dr Reddy's Laboratories (RDY) Highlighted As Weak On High Volume

Dr Reddy's Laboratories (RDY) Highlighted As Weak On High Volume

Trade-Ideas LLC identified Dr Reddy's Laboratories (RDY) as a weak on high relative volume candidate

Ex-Dividend Alert: 3 Stocks Going Ex-Dividend Tomorrow: GLV, GLO, RDY

Ex-Dividend Alert: 3 Stocks Going Ex-Dividend Tomorrow: GLV, GLO, RDY

GLV GLO RDY are going ex-dividend tomorrow, Thursday, July 14, 2016

Dr. Reddy's To Release Q1 FY17 Results On July 26, 2016  Earnings Call Slated For July 26, 6.30 PM IST / 9.00 AM EDT

Dr. Reddy's To Release Q1 FY17 Results On July 26, 2016  Earnings Call Slated For July 26, 6.30 PM IST / 9.00 AM EDT

Dr. Reddy's Laboratories (NYSE: RDY | NSE: DRREDDY | BSE: 500124) will announce results for the First Quarter ended June 30, 2016 on Tuesday, July 26, 2016 after the Board Meeting.

What Exactly Did Allergan and Teva Sell to Impax?

What Exactly Did Allergan and Teva Sell to Impax?

The deal helps the Israeli drug giant comply with required antitrust divestitures connected to completion of its $40.5 billion acquisition of the generics business of Allergan.

Bearish Bets: 5 Mixed Stocks That Look Good Short

SCCO, RDY, FLR, REV and MFRM were all recently downgraded by TheStreet’s Quant Ratings.

Teva's Suspension of Marketing for Zecuity Product is Likely to Have Little Impact

Teva's Suspension of Marketing for Zecuity Product is Likely to Have Little Impact

Teva Pharmaceuticals said Monday it will voluntarily suspend marketing of its Zecuity migraine relief product after receiving reports of adverse skin reactions.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: NEWS, SSRI, TSE Downgrades: AL, BX, FINL, FLR, LYG, MAGS, RDY, STRT, TOT Initiations: ANTX, JAGX Read on to get TheStreet Quant Ratings' detailed report:

Dr. Reddy's To Acquire Product Portfolio From TEVA For US Market

Dr. Reddy's To Acquire Product Portfolio From TEVA For US Market

Dr. Reddy's Laboratories (BSE:500124, NSE:DRREDDY, NYSE:RDY) has entered into a definitive agreement with Teva Pharmaceutical Industries Ltd.

Promius Pharma Launches Sernivo™ (betamethasone Dipropionate) Spray, 0.05%

Promius Pharma Launches Sernivo™ (betamethasone Dipropionate) Spray, 0.05%

Dr. Reddy's Laboratories announced today that its US subsidiary, Promius Pharma, LLC, U.

Xenoport's Cost-Cutting Tactics Lead to Buyout With Hefty Premium

Xenoport's Cost-Cutting Tactics Lead to Buyout With Hefty Premium

The biotechnology company, which makes alcoholism drug Horizant, was acquired by privately held Arbor Pharmaceuticals for $467 million in cash, a price lower than at least one analyst expected.

Dr. Reddy's Q4 And FY16 Financial Results

Dr. Reddy's Q4 And FY16 Financial Results

Dr. Reddy's Laboratories Ltd.

Dr. Reddy's Laboratories Announces The Appointment Of Mr. Bharat Doshi As An Additional Independent Director On The Board Of The Company

Dr. Reddy's Laboratories Announces The Appointment Of Mr. Bharat Doshi As An Additional Independent Director On The Board Of The Company

Mr. Bharat Doshi has been appointed as an Additional Independent Director on the Board of Dr.

Dr. Reddy's To Release Q4 And Full Year FY16 Results On May 12, 2016; Earnings Call Slated For May 12, 6.30 PM IST / 9.00 AM EDT

Dr. Reddy's To Release Q4 And Full Year FY16 Results On May 12, 2016; Earnings Call Slated For May 12, 6.30 PM IST / 9.00 AM EDT

Dr. Reddy's Laboratories (NYSE: RDY; NSE: DRREDDY; BSE: 500124) will announce results for the Fourth Quarter and Full Year ended March 31, 2016 on Thursday, May 12, 2016 after the Board Meeting.

ZEMBRACE™ SymTouch™ (Sumatriptan Injection) 3 Mg, Approved By The FDA In January 2016 For The Acute Treatment Of Migraine With Or Without Aura In Adults, Is Now Commercially Available In The U.S.

ZEMBRACE™ SymTouch™ (Sumatriptan Injection) 3 Mg, Approved By The FDA In January 2016 For The Acute Treatment Of Migraine With Or Without Aura In Adults, Is Now Commercially Available In The U.S.

Promius Pharma LLC, a subsidiary of Dr. Reddy's Laboratories (BSE: 500124, NSE: DRREDDY, NYSE: RDY), announced today that ZEMBRACE SymTouch is now commercially available in the U.

Cutispharma, Dr. Reddy's Laboratories Announce Partnership

Cutispharma, Dr. Reddy's Laboratories Announce Partnership

Joint development agreement will accelerate NDA filing and worldwide commercialization of select products in CutisPharma's R&D portfolio

Dr. Reddy's Laboratories Acquires The Rights To Investigational Anticancer Agent E7777 For U.S., Europe And Certain Emerging Markets From Eisai

Dr. Reddy's Laboratories Acquires The Rights To Investigational Anticancer Agent E7777 For U.S., Europe And Certain Emerging Markets From Eisai

Dr. Reddy's Laboratories (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that it has entered into a licensing agreement with Eisai Co.

Dr. Reddy's Laboratories And XenoPort Enter Into A U.S. Licensing Agreement For XP23829

Dr. Reddy's Laboratories And XenoPort Enter Into A U.S. Licensing Agreement For XP23829

Dr. Reddy's Laboratories (BSE: 500124, NSE: DRREDDY, NYSE: RDY) and XenoPort, Inc.

Dr. Reddy's Laboratories And XenoPort Enter Into A U.S. Licensing Agreement For XP23829

Dr. Reddy's Laboratories And XenoPort Enter Into A U.S. Licensing Agreement For XP23829

Dr. Reddy's Laboratories (BSE: 500124, NSE: DRREDDY, NYSE: RDY) and XenoPort, Inc.

Dr. Reddy's And TR-Pharm Announce Strategic Collaboration In Turkey

Dr. Reddy's And TR-Pharm Announce Strategic Collaboration In Turkey

Dr. Reddy's and TR-Pharm announced today a strategic collaboration agreement involving 3 biosimilar products.